Chinese patent medicine
Chinese patent medicine (CPM, simplified Chinese: 科学中药; traditional Chinese: 科學中藥; pinyin: kēxúe zhōngyào; lit. 'scientific Chinese medicine' or simplified Chinese: 中成药; traditional Chinese: 中成藥; pinyin: zhōngchéngyào; lit. 'pre-made Chinese medicine')[a] are herbal medicines in traditional Chinese medicine (TCM), modernized into a ready-to-use form such as tablets, oral solutions or dry suspensions, as opposed to herbs that require cooking (hot water extraction).
History
[edit]Traditional Chinese medication generally begins with a liquid extract of a mixture of prepared herbs (饮片), produced by a long period of boiling in water or a mixture of water and alcohol. Some formulas require different extraction times for each herb, leading to a complicated sequence of adding ingredients. With formulas intended for internal use, the resulting decoction (Tang 汤) is typically drunk directly. Some classical formulas call for turning the decoction into a ready-made teapill (Wan or Dan) for easier use. Formulas intended for external use, such as the gou pi gao, calls for more involved post-processing.
Chinese patent medicine started as a simplified way to produce a decoction. In the 1950s, Japanese man Otozo Nagakura founded a business that makes Kampo medicine in granule form by dehydrating the extract liquid. Patients would simply re-hydrate the granules and drink the resulting fluid. Taiwanese man Xu Hong-yuan visited Nagakura's factory and was impressed by its convenience and efficiency, bringing the technology to Taiwan.[1]
Xu Hong-yuan later also invented the single-herb "granules for use in combination", which grants similar convenience to customized prescriptions. (Per-patient formulation is emphasized in TCM.)[1] Chinese use of single-herb granules is growingly common, but technically remains experimental.[1]
In China
[edit]The 1963 edition of the Chinese Pharmacopoeia lists more than 150 so-called "pre-made prescriptions" (中药成方) in traditional liquid, paste, Wan (丸) pill, and Dan (丹) pill forms.[2] The next edition of 1977 includes more obviously "modernized" forms: tablets, sprays, granules, and even injections.[3]
Forms
[edit]This section needs additional citations for verification. (October 2011) |
Traditional forms
[edit]A few forms used in standardized, ready-to-use traditional Chinese medicine are inherited from the classical works. These include extracted condensed pills called teapills, honey pills and water pills made from ground raw herbs, mixture of powders (San), and plasters (Gao).
Teapills are usually small, spherical, and black. They gain their name because the herbs are cooked into a herbal tea to make the pills. Modern teapills are created from herbs extracted in stainless steel extractors to create either a water decoction or water-alcohol decoction, depending on the herbs used. They are extracted at a low temperature (below 100 degrees Celsius; 212 degrees Fahrenheit) to preserve essential ingredients. The extracted liquid is then further condensed and a small amount of raw herb powder from one of the herbal ingredients is mixed in to form a herbal dough. This dough is then cut into tiny pieces by a machine, and a small amount of excipients are added for a smoother and a more consistent exterior. The products are then made as pills.
Honey or water pills made from ground raw herbs are also a popular format in China, and they tend to be larger and are slightly to significantly softer than teapills. Honey pills and water pills have been made since ancient times by combining several dried herbs and other ingredients, which are grounded into powder, mixed with a binder and traditionally formed into pills by hand. Modern honey or water pills are formed into pills by machine. The binder is traditionally honey for honey pills. For water pills the binder may simply be water, or may include another binder, such as molasses. Modern manufacturers still produce many patent formulas as honey or water pills, such as Wuji Baifeng Wan, a popular honey pill formula to "nourish qi and blood", to strengthen the body.
Newer forms
[edit]As mentioned in the "History" section, the original form of Chinese patent medicine is the extract granule. A granule can be reconstituted with water much like an instant tea. Granules are made by drying a decoction and serve as a more convenient form the decoction, with no prolonged boiling needed. Sugar is often added as excipient and sweetener.[4] Similarly, a powder derived from drying a decoction can be pressed into a tablet or packaged into a capsule.[5]
Another form that only became common with modern packaging is the liquid. The liquid can be water-based similar to the tea used to make the teapill, or be an alcohol-based extract of herbs. 十滴水 "ten drops of water", a medication supposedly for heat illness, is an alcohol-based liquid. It has also been packaged into a softgel.[6]
Forms for use in combination
[edit]Some forms of Chinese patent medicine is not intended for direct use by the patient, but are extracts for mixing with other herbs or extracts to produce a customized formula. When each boiled-extract corresponds to one single herb, they can be mixed together according to a traditional Chinese medicine prescription, substituting the herbs to be boiled with a corresponding amount of the extract. The main example of this class is "granules for use in combination" (中药配方颗粒) – granules made from drying a decoction. These forms give the no-boil convenience of CPMs to TCM practitioners who provide customized prescriptions for each patient.[1]
Fixed-formula Chinese patent medicine have also made use of similar approaches to simplify manufacture and to use more modern extraction methods. For example, volume 1 of the Chinese Pharmacopoeia (which deals with TCM and CPM) includes such ingredients as a rhubarb extract (extracted using hot water-ethanol mixture), a ginkgo leaf extract (extracted using a dilute water solution of ethanol), and a total ginsenoside [from] ginseng root (extracted through column chromatography).[7]
Injections
[edit]A phenomenon mostly confined to China is the use of TCM-derived fluids for injection. Originally an attempt at rationing herb use during the Second Sino-Japanese War,[8] numerous TCM-derived injections have been formulated and used in China. By the 1980s, as many as 1400 different injections are on the market.[9] In the 1980s, a stronger regulatory framework was established for these injections. Reports of severe adverse effects have encouraged further improvements in regulation,[10] with safety re-evalulation started in 2009.[11][12] Another re-evaluation, this time combining safety and effectiveness, was started in 2017.[13] In 2022, Lian Bi Zhi injection became the first TCM injection to be delisted due to failing postmarket re-evaluation.[14]
The most common adverse effect events for TCM injections are fevers, allergy, and allergy-like symptoms (e.g. mediated through mast cell or complement system), with the last being the most common.[15][16] One particularly serious offender, Houttuynia cordata injection, has caused 22 deaths through anaphylactic shock in a span of 2 years.[17] Its package insert has since been modified to remove intravenous use as an accepted route, leaving intramuscular only.[18]
National regulatory infrastructure now exists for collecting reports of adverse effects. The proportion of injection-related adverse events in all TCM-related adverse events is trending down since 2017.[19]
Regulation
[edit]Like other patent medicines, they are not necessarily patented in the traditional sense of the word. Typically no-one has exclusive rights to the formula.[b] The term patent medicine is borrowed to refer to their often unclear effectiveness. Unlike Western "patent medicine" of old, these products have a fixed proportion of ingredients, as they are put under a modern regulatory framework.
China
[edit]In China, all Chinese patent medicines of the same name have the same proportions of ingredients, and are manufactured in accordance with the PRC Pharmacopoeia's monograph on that particular formula, which is mandated by Chinese law. Each monograph details the exact herbal ingredients that make up the patent formula, usually accompanied by the specific tests that should be used for correct herb identification, such as thin layer chromatography (TLC) or high performance liquid chromatography (HPLC), the percentage of each ingredient, and specific cautions and contraindications. The monograph also details the manufacturing methods that must be followed, how to process and cook the herbs, often including specific requirements for finished product testing including authenticating and assessing the potency of the formula with active ingredient markers where known, as well as testing for dissolution time and content uniformity. All good manufacturing practice (GMP) certified factories must also test for heavy metal levels and microbials for all patent medicines they produce.[21]
However, many patent medications do not list all ingredients, presumably to protect the secrecy of the formula. An example of this is Yunnan Baiyao, a popular formula used to stop bleeding, whose ingredients have never been revealed. This is an acceptable practice in China, where no other protection exists to protect family or "secret" Chinese herbal formulas. The state has access to the Yunnan Baiyao formula for regulatory purposes.
Taiwan
[edit]Japan
[edit]Traditional Chinese medicine entered Japan in the 7th century and has been developing on its own as Kampō. As mentioned earlier, the practice of producing ready-to-use granules originated in Japan. The Ministry of Health, Labour and Welfare manages a Kampo list which contains specific approved forms of mixed and single-herb herbal medicine.[22] In October 2000, a nationwide study reported that 72% of registered physicians prescribe Kampō medicines.[23]
Other countries
[edit]In western countries, there is considerable variation of ingredients and in the proportions of ingredients in products sharing the same name. This is because the Chinese government allows foreign companies to apply for modifications of patent formulas to be sold outside of China. For example, Hebei brand Lifei pills contain Kadsura (feng sha teng) and Morus (sang ye), whereas Plum Flower brand Li Fei Pian contains Schizandra (we wei zi) and Gecko (ge jie) instead. Another example is Qing Qi Hua Tan Wan. The Lanzou brand uses Citrus (ju hong). The Lanzhou Foci Min Shan brand and the Plum Flower brand do not, but use Ginger (sheng jiang).
Herbal formulas
[edit]Chinese classic herbal formulas form the basis of Chinese patent medicine. These are the basic herbal formulas that students of traditional Chinese medicine learn. Many of these formulas are quite old. For example, "Liu Wei Di Huang Wan" (六味地黄丸 liù wèi dì huáng wán) was developed by Qian Yi (钱乙 Qián Yǐ) (c. 1032–1113 CE). It was published in the "Xiao'er Yao Zheng Zhi Jue" (also known as "Key to Therapeutics of Children's Diseases" 小儿药证直诀 xiǎoér yào zhèng zhí jué) in 1119 by Qian Yi's student. Although Liu Wei Di Huang Wan can be prepared as a raw herb decoction (or herbal tea), it was originally created to be made into honey pills. The last word in Liu Wei Di Huang Wan, "Wan" (丸) means "pill".[21][24]
Under Chinese regulations, non-injection-type CPM applications based on a classical formula are given a fast-tracked approval process. The usual clinical studies for effectiveness and safety can be omitted, and only a pre-clinical safety study is required.[25] More than a dozen new CPMs are approved every year, some based on classical formulas, others new inventions.[26]
Criticisms
[edit]Heavy metal contamination
[edit]Some Chinese patent medicines were tested and found to contain high to dangerous levels of heavy metals.[27] The most common heavy metals found were mercury, lead, and arsenic. These ingredients can cause serious medical problems.
Many heavy metal contaminants named in the context of herbal medicine is intentionally added and declared on product labels. The mercury salt cinnabar (Chinese: 朱砂; pinyin: zhūshā), the arsenic salt realgar (Chinese: 雄黄; pinyin: xíong huáng) and the strychnine-containing Strychnos nux-vomica (Chinese: 马钱子; pinyin: Mǎqiánzǐ) are used traditionally and kept in China despite the known harm and little proven benefit.[28]
Pharmaceutical adulterants
[edit]Some Chinese patent medicines were found to contain pharmaceutical drugs such as decongestants, analgesics or antihistamines. The most common Chinese patent medicines found to carry pharmaceutical drugs were for the treatment of asthma, pain, and arthritis.[27]
Many drug adulterants are intentionally added and declared on product labels. For example, the entry for "Vitamin C/Lonicera/Forsythia tablet" (Chinese: 维C银翘片; pinyin: Wéi C Yínqiào Piàn) in the Chinese Pharmacopoeia (ChP) calls for 105 mg of paracetamol and 1.05 mg of chlorpheniramine maleate each pill. Such a combination is common for Chinese cold medicine. In a more hidden case, the herb Ephedra naturally contains ephedrine and pseudoephedrine, and is required by the ChP to have more than 0.8% of the two decongestants (as hydrochloride salts) in its dry weight.[28]
Prohibited ingredients
[edit]Some Chinese patent medicines contain ingredients which are banned in other countries. The two most common prohibited herbs are Ephedra (麻黄 máhuáng) (Ephedra) and Ban Xia (半夏 bànxià) (Pinellia). On 30 December 2003, the FDA in the US announced a ban (effective 12 April 2004), on these herbs from all dietary supplements.[29] Traditional Chinese herbal remedies are exempt from this law.[citation needed]
The 2020 version of the Chinese Pharmacopoeia removed pangolin scale and Aristolochia debilis from allowed ingredients.
Regulation
[edit]In Taiwan
[edit]In modern-day Taiwan, regulations to address the criticisms are introduced due to Chinese patent medicines being prescription drugs since the 1970s and a part of the public health system since 1995.
Taiwan Herbal Pharmacopeia (ISBN 9789860354157) provides information on acceptable herbs in Taiwan.
Heavy metal contamination and pesticide residue
[edit]All Chinese patent medicine products sold in Taiwan must pass a heavy metal limitation test and pesticide residue test according to Taiwan Herbal Pharmacopeia. There are several manufacturers in Taiwan certified ISO 17025 Lab, for example: Sun-Ten (順天堂), Chuang Song Zong Pharmaceutical Co., Ltd. (Chinese: 莊松榮)
Pharmaceutical adulterants
[edit]According to Taiwanese government law, products licenses will be suspended if there exists pharmaceutical adulterants. Furthermore, it could cause GMP certificate to be cancelled. In Taiwan, those main manufacturer in order to export products abroad, few of them has passed PIC/S GMP audition. For example: Sun-Ten (Chinese: 順天堂), Chuang Song Zong Pharmaceutical Co., Ltd. (Chinese: 莊松榮).
In China
[edit]As with more traditional formulae, standards for Chinese patent medicine are found in Volume 1 of Chinese Pharmacopoeia. Some of the resultant medications require a prescription to purchase, while others are considered over-the-counter drugs. Heavy metal limits are present for a few herbs, although they tend to be laxer than those defined for foods. As listed above, intentionally added heavy metals and drug adulterants are found in many products.[28]
References
[edit]- ^ As can be glanced from the difference in literal meaning, there exists a definitional gap between the Taiwanese "scientific" term and the Chinese/Hongkongese "pre-made" term. The Taiwanese term is defined exclusive of traditional ready-to-use forms such as the Wan, Dan, and Gao, while the Chinese term includes all ready-made, batch-manufactured TCM-based medicine.
- ^ A patent can still be applied to a newly-formulated Chinese patent medicine, which is the case for Xinyue capsule, a preparation of American ginseng leaf-and-stem ginsenosides introduced in 2003.[20]
- ^ a b c d JIANG, YG. "免煎药:瑞士中药推广功臣". 中国中医药网.
- ^ 中华人民共和国卫生部药典委员会 (1965). 中华人民共和国药典一部 (1963 ed.).
- ^ 中华人民共和国卫生部药典委员会 (1977). 中华人民共和国药典一部 (1979 ed.).
- ^ "乙肝宁颗粒". 中国药典. Vol. 1 (2020 ed.). p. 448. – This is an arbitrarily-chosen CPM in granule format. This formula supposedly treats hepatitis B.
- ^ For examples, see chapters 十一味参芪片 and 十一味参芪胶囊, which documents the manufacturing process of a tablet and a capsule both based on the same TCM combination. Volume I of the 2020 ChP (Chinese edition), pp 459, 460.
- ^ "十滴水软胶囊". 中国药典. Vol. 1 (2020 ed.). p. 470. – This is a PRC Pharmacopoeia monograph. It specifies the proportion of ingredients and the process of manufacture.
- ^ 中国药典 Vol 1 2020 edition. Chapters 大黄浸膏, 银杏叶提取物, 人参总皂苷. Pages 413, 434, 409.
- ^ 任德权 (2010). "理性看待中药注射剂促其科学发展" [A rational look at TCM injections encourages its scientific development]. 中国循证医学杂志. 10 (2): 105–106. Retrieved 2015-10-07.
- ^ 白晓菊 (2008). "中药注射剂现状分析与发展对策" [Current state of TCM injections and development pathways]. 中药药理与临床. 24 (5).
- ^ Ji, Kunmei; Chen, Jiajie; Li, Meng; Liu, Zhigang; Xia, Lixin; Wang, Chunbo; Zhan, Zhengke; Wu, Xuli (November 2009). "Comments on serious anaphylaxis caused by nine Chinese herbal injections used to treat common colds and upper respiratory tract infections". Regulatory Toxicology and Pharmacology. 55 (2): 134–138. doi:10.1016/j.yrtph.2009.06.008. ISSN 0273-2300. PMC 7117048. PMID 19559066.
- ^ "关于印发中药、天然药物注射剂基本技术要求的通知" [On printing and distributing "Baseline technical requirements for TCM and natural medication injections"]. www.nmpa.gov.cn. Archived from the original on 2023-01-01. Retrieved 2024-08-13.
- ^ "关于开展中药注射剂安全性再评价工作的通知" [On starting safety re-evaluation of TCM injections]. www.nmpa.gov.cn. Retrieved 2024-08-13.
- ^ "中共中央办公厅 国务院办公厅印发《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》" [On printing and distributing "Opinion on deepening the reform of the drug and medical instrument approval process"]. www.gov.cn. Archived from the original on 2024-08-13. Retrieved 2024-08-13.
- ^ "国家药监局关于注销莲必治注射液药品注册证书的公告(2022年第2号)" [On delisting Lian Bi Zhi injection from the drug registry]. www.nmpa.gov.cn. Retrieved 2024-08-13.
- ^ 易艳; 田婧卓; 李春英; 赵雍; 梁爱华 (2022). "中药注射剂上市后非临床安全性再评价类过敏反应相关研究" [Study on allergy-like symptoms encountered during TCM injection postmarket re-evaluation]. 中国药物警戒. 19 (2): 185-188+204. doi:10.19803/j.1672-8629.2022.02.15. Archived from the original on 2024-08-23. Retrieved 2024-08-17.
- ^ 易艳; 李春英; 赵雍; 梁爱华 (2021). "中药注射剂不良反应及类过敏反应研究进展" [Progress in the research of allergy and allergy-like symptoms caused by TCM injection]. 中国中药杂志. 46 (7). doi:10.19540/j.cnki.cjcmm.20201015.602.
- ^ 吴健鸿; 杨晓燕; 柳强妮; 尹平; 曾繁典 (2016). "鱼腥草制剂上市后安全性再评价" [Postmarket safety re-evaluation of Houttuynia cordata injection]. 医药导报. 35 (8): 803-808.
- ^ "关于鱼腥草注射液等7个注射剂有关处理决定的通知" [On regulatory decisions applied to 7 injections including Houttuynia cordata injection]. 国食药监办[2006]461号. Archived from the original on 2015-01-23. Retrieved 2013-01-12.
- ^ a b Zheng, Wenwen; Wu, Yiyang; Gao, Hanlu; Ouyang, Defang (2022-11-08). "Traditional Chinese medicine injections: where we are after 80-year development". Chinese Medicine. 17 (1): 127. doi:10.1186/s13020-022-00681-w. ISSN 1749-8546. PMC 9640875. PMID 36348487.
- ^ Guo, M; Wang, P; Du, J; Fu, C; Yang, Q; Gao, Z; Zhu, M; Lv, S; Deng, Y; Li, T; Shi, D; Working Group, FTX (August 2020). "Xinyue Capsule in patients with stable coronary artery disease after percutaneous coronary intervention: a multicenter, randomized, placebo-controlled trial". Pharmacological Research. 158: 104883. doi:10.1016/j.phrs.2020.104883. PMID 32446979. – cited for patent status
- ^ a b State Pharmacopoeia Commission of the PRC (2005). "Pharmacopoeia of The People's Republic of China (Volume I)". Chemical Industry Press. ISBN 7117069821[page needed]
- ^ Kotoe Katayama; et al. (2013). "Prescription of Kampo Drugs in the Japanese Health Care Insurance Program" (PDF). Evidence-Based Complementary and Alternative Medicine. 2013. Hindawi Publishing Corporation: 576973. doi:10.1155/2013/576973. PMC 3914391. PMID 24550992. Retrieved August 25, 2014.
- ^ "Legal Status of Traditional Medicine and Complementary/Alternative Medicine:A Worldwide Review" (PDF). 2001. pp. 155–159. Archived from the original (PDF) on September 27, 2009. Retrieved August 25, 2014.
- ^ Chinese Medicine Guide, 3 September 2023
- ^ "4000亿中成药市场腾飞!临床价值成"最强核心","古方新药"大有可为" [400-billion-yuan CPM market goes flying! Clinical value is the strongest core, and "classical formula new drugs" have much to win]. finance.sina.com.cn. 2024-07-22.
- ^ "2021年中国中药创新药行业市场现状分析,医保中药扶持逐渐加强「图」_华经情报网_华经产业研究院" [Analysis of the CPM new drug industry in 2021: Strengthening support from the national health insurance system]. www.huaon.com.
- ^ a b Adulteration and Contaminants in Chinese Patent Medicines Archived December 8, 2006, at the Wayback Machine
- ^ a b c Chinese Pharmacopoeia. 2015. ISBN 978-7-5067-7337-9. 1:50,137,320,336,1570.
- ^ http://www.fda.gov/oc/initiatives/ephedra/february2004/ "Sales of Supplements Containing Ephedrine Alkaloids (Ephedra) Prohibited". Food and Drug Administration. Archived from the original on February 10, 2007. Retrieved October 30, 2008.
{{cite web}}
: CS1 maint: bot: original URL status unknown (link) Sales of Supplements Containing Ephedrine Alkaloids (Ephedra) Prohibited]
- Fratkin, Jake (2001). Chinese Herbal Patent Medicines. Shya Publications. ISBN 0-9626078-4-3.
- Taylor, Mark (1998). Chinese Patent Medicines: A Beginner's Guide. Global Eyes International Press. ISBN 0-9662973-0-X.
- Taiwan herb pharmacopeia
See also
[edit]- Kampo (Japanese adaptation of Chinese medicine)
- Kampo list (list of Japanese versions of Chinese patent medicines)